| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 15.255 | 15.646 | 18.175 | 11.610 | 17.534 | 156.562 | 14.047 | 8.364 | 11.345 | 2.483 |
| Total Income - EUR | 15.258 | 15.651 | 18.176 | 11.611 | 17.534 | 156.564 | 14.124 | 8.364 | 11.346 | 2.483 |
| Total Expenses - EUR | 9.151 | 7.040 | 8.403 | 9.395 | 8.738 | 120.348 | 15.109 | 7.525 | 14.051 | 14.149 |
| Gross Profit/Loss - EUR | 6.108 | 8.611 | 9.774 | 2.216 | 8.796 | 36.216 | -984 | 840 | -2.705 | -11.666 |
| Net Profit/Loss - EUR | 5.650 | 8.153 | 9.228 | 1.866 | 8.270 | 31.855 | -1.380 | 614 | -2.705 | -11.666 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Alnimed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.032 | 2.011 | 1.977 | 1.941 | 2.370 | 4.947 | 3.996 | 3.357 | 3.393 | 2.842 |
| Current Assets | 31.576 | 27.008 | 36.565 | 43.495 | 45.253 | 80.824 | 78.271 | 76.540 | 64.979 | 45.027 |
| Inventories | 0 | 704 | 2.401 | 2.231 | 2.234 | 2.088 | 2.018 | 2.017 | 2.659 | 1.019 |
| Receivables | 11.944 | 16.037 | 23.499 | 30.295 | 33.288 | 75.050 | 67.037 | 73.848 | 60.989 | 42.892 |
| Cash | 19.631 | 10.267 | 10.665 | 10.969 | 9.731 | 3.686 | 9.216 | 675 | 1.331 | 1.116 |
| Shareholders Funds | 22.516 | 20.864 | 29.739 | 31.059 | 38.727 | 69.848 | 66.920 | 61.658 | 58.767 | 46.772 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 11.092 | 8.155 | 8.803 | 14.377 | 8.896 | 15.923 | 15.347 | 18.238 | 9.606 | 1.097 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Alnimed S.r.l.